Popular Articles
Cellulite Treatment

Maryland Stem Cell Research Commission Announces 59 Projects For Funding
The Maryland Stem Cell Research Commission (Commission) has completed its evaluation of the 147 applications in response to its three official Requests for Applications (RFAs). The board of directors of the Maryland Technology Development Corporation (TEDCO) reviewed the Commission"s recommendations today and approved 59 projects totaling $18.9 million in funding through the Maryland Stem Cell Research Fund (MSCRF) under the Maryland Stem Cell Research Act of 2006.
generic viagra online
Lower Empathic Responses To Outsiders' Pain Shown By Imaging Study
An observer feels more empathy for someone in pain when that person is in the same social group, according to new research in the July 1 issue of The Journal of Neuroscience. The study shows that perceiving others in pain activates a part of the brain associated with empathy and emotion more if the observer and the observed are the same race. The findings may show that unconscious prejudices against outside groups exist at a basic level.
News of the day
Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect").
Mental Health

Shire Selects SAS(R) Drug Development To Handle Clinical Trials Data

SAS, the leader in business analytics, announced that Shire, the global specialty biopharmaceutical company, has selected SAS® Drug Development as the platform for its clinical trials data. "Shire is excited about our partnership with SAS, and we look forward to leveraging the SAS Drug Development platform to manage our clinical trial data," said Nick Ronca, Associate Director Clinical R&D, Shire Pharmaceuticals. SAS Drug Development is available as a standalone or hosted solution with access via a secure, thin client. A centralized repository allows life sciences firms to aggregate, analyze and review clinical trials data to determine safety and efficacy outcomes. "Our approach at SAS allows our customers, like Shire, to be more focused and efficient in developing and delivering medicines to patients and their families around the world," said Jason Burke, Global Director of Health and Life Sciences for SAS. 21 CFR and CDISC Compliant SAS Drug Development allows rapid and reliable validation and implementation, eliminating strain on limited IT infrastructure and res. The solution is compliant with global agency regulations, such as 21 CFR Part 11, which is often difficult to attain. "Our hosted global environment contains a single view of the targeted clinical data in a secured and qualified environment so scientists, programmers and statisticians can view the most up-to-date, accurate information" said Burke. SAS" scalability and flexibility were features important to Shire, which has grown rapidly through acquisitions and mergers over its nearly twenty-five year history. Shire, which has a presence in 23 countries and markets medicines in more than 45 countries, needed a global solution for managing and processing its clinical trial data. "Working in unison with SAS allows Shire to focus on meeting its mission, and investing in its product portfolio instead of developing a complex IT infrastructure to support clinical data," said Burke. SAS Implementation Team Relying on the SAS Consulting Group that has successfully deployed SAS Drug Development in the past, Shire believes that the system will maximize the best practices of both Shire and SAS. SAS is demonstrating SAS Drug Development at the DIA 45th Annual Meeting in Booth 301. SAS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):